Masimo Corp. Stock
€156.00
Your prediction
Masimo Corp. Stock
Pros and Cons of Masimo Corp. in the next few years
Pros
Cons
Performance of Masimo Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Masimo Corp. | - | - | - | - | - | - | - |
| Haemonetics Corp. | 0.000% | 3.125% | 12.821% | - | -3.650% | - | - |
| Bio-Rad Labs Inc. A | -2.010% | 9.756% | -0.609% | 24.049% | 1.202% | -24.870% | -52.973% |
| CONMED Corp. | 0.000% | -8.387% | -4.054% | -35.160% | -18.857% | -77.280% | -75.517% |
Comments
News
This $7 Million Masimo Exit Came Before a 34% Surge on $9.9 Billion Acquisition
On February 17, 2026, Bridger Management disclosed in a Securities and Exchange Commission (SEC) filing that it sold out its entire position in Masimo (NASDAQ:MASI).
According to a Securities and
This Fund Built a $26 Million Stake in a Medical Tech Stock That's Soaring After a $9.9 Billion Deal Announcement
On February 17, 2026, Parkman Healthcare Partners disclosed a new position in Masimo Corporation (NASDAQ:MASI), acquiring 200,000 shares in the fourth quarter worth an estimated $26.01 million at
Naya Capital Adds Masimo Shares
According to an SEC filing dated Feb. 18, Naya Capital Management UK Ltd disclosed a new position in Masimo (NASDAQ:MASI), acquiring nearly 1.6 million shares.
Masimo is a leading provider of


